China’s pharmaceutical industry is facing a new wave of compliance pressure as authorities intensify enforcement of anti-corruption rules aimed at eliminating disguised payments, improper business practices, and integrity failures in drug development.

The strengthened enforcement focus under the second judicial interpretation on commercial bribery, known as Interpretation II, has increased compliance risks for pharmaceutical companies, medical institutions, and industry intermediaries. Regulators are paying closer attention to practices that have historically been used to conceal improper benefits, including sham consulting arrangements, inflated service payments, and unreliable clinical research data.

For pharmaceutical companies operating in China, the message is clear: compliance expectations are moving beyond formal policies and into the substance of business activities. Regulators are examining whether transactions have genuine commercial purpose, whether payments reflect legitimate services, and whether internal controls can prevent corruption risks before they occur.

From Hidden Payments to High-Risk Controls

One of the major areas of scrutiny is the use of consulting fees and third-party service arrangements. While legitimate consulting relationships remain an important part of pharmaceutical operations, regulators are increasingly focused on arrangements that may exist primarily as channels for transferring improper benefits.

Payments to healthcare professionals, external advisers, research organisations, and other intermediaries are receiving greater attention because they can create opportunities for disguised influence.

Compliance teams are now expected to demonstrate that third-party engagements are supported by clear business needs, documented deliverables, appropriate compensation structures, and effective oversight.

A contract alone is no longer enough. Companies must be able to prove that services were actually performed and that payments were reasonable and transparent.

Clinical Data Integrity Under the Spotlight

The crackdown also highlights growing concerns around the reliability of clinical research information. Accurate clinical data is essential for patient safety, regulatory approval, and public confidence in pharmaceutical products.

Any manipulation, falsification, or inadequate control over clinical trial information can create significant legal, financial, and reputational consequences.

Pharmaceutical companies must therefore strengthen governance over the entire research lifecycle, including data collection, validation, storage, reporting, and oversight of external research partners.

Data integrity is becoming a core compliance obligation, linking regulatory compliance with broader corporate ethics and patient protection responsibilities.

Compliance Moves Into the Boardroom

The changing enforcement environment requires pharmaceutical executives and boards to reassess their compliance frameworks. Anti-corruption controls can no longer operate as isolated legal functions; they must be integrated into business decision-making.

Senior leadership is expected to ensure that compliance programmes have adequate resources, independent oversight, and the authority to challenge risky commercial practices.

Areas requiring increased attention include:

• Third-party due diligence and monitoring
• Healthcare professional interactions
• Marketing and sales practices
• Consulting and advisory payments
• Clinical research governance
• Data management controls

Companies that fail to identify weaknesses in these areas may face regulatory action, financial penalties, operational disruption, and damage to corporate reputation.

The Third-Party Risk Challenge

The pharmaceutical sector relies heavily on external partners, including distributors, research organisations, consultants, and service providers. These relationships create efficiency but also introduce compliance exposure.

Under stronger enforcement conditions, companies must understand not only their direct employees’ conduct but also the activities of organisations acting on their behalf.

Effective third-party compliance requires risk-based screening, transparent contracting, ongoing monitoring, and clear accountability.

The inability to explain why a third party was selected, what services were provided, or whether payments were appropriate can become a significant regulatory vulnerability.

A New Era of Pharmaceutical Accountability

China’s intensified anti-corruption enforcement reflects a wider global trend: pharmaceutical companies are facing increasing expectations around transparency, ethical conduct, and responsible governance.

The industry’s compliance challenge is no longer limited to avoiding violations. It is about building systems that demonstrate integrity throughout the value chain — from research and development to commercialisation and market engagement.

For pharmaceutical companies, the lesson is straightforward: compliance must be embedded into operations, not added after problems emerge.

As regulators continue to examine the connections between money, influence, and healthcare decision-making, organisations with strong governance, transparent processes, and proactive risk management will be best positioned to navigate the new compliance environment.

Compliance Takeaway

China’s strengthened pharmaceutical anti-corruption enforcement shows that regulators are focusing on the substance behind business activities, not just documentation. Pharma companies should strengthen third-party controls, validate consulting arrangements, protect clinical data integrity, and ensure senior leadership actively oversees anti-bribery compliance.